1st Quarter - Amendment

CORNING INCORPORATED for CORNING INCORPORATED

Firm
Client
Income
—
Expenses
$380,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 20, 2017 $370,000 Replaced
1st Quarter - Amendment (this page) Mar 20, 2019 $380,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

PL 114-183, PIPES Act of 2016 - Section 3, Regulatory Updates.

LobbyistCovered position, as disclosed
STANLEY G FENDLEY —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Telecommunications TEC

Broadband components of infrastructure (no legislation introduced yet).

LobbyistCovered position, as disclosed
TIMOTHY J REGAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Environment/Superfund ENV

FY17/18 EPA Appropriations (no Appropriations Bills introduced yet).

LobbyistCovered position, as disclosed
TIMOTHY J REGAN —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

Tariff and non-tariff barriers on optical fiber; WTO; Environmental Goods Agreement (EGA); APEC; China market access; Trade secrets protection; India Trade; Investment; Taiwan Trade, and NAFTA.

LobbyistCovered position, as disclosed
DEBRA WAGGONER —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE

Taxation/Internal Revenue Code TAX

Tax reform proposals.

LobbyistCovered position, as disclosed
STANLEY G FENDLEY —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Impact of 28 USC 1782 on IP protections.

LobbyistCovered position, as disclosed
STANLEY G FENDLEY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Health Issues HCR

Implementation of H.R. 34 (PL 114-255), 21st Century Cures Act, NIH funding section (no Appropriations Bills introduced yet); FDA issues (no legislation introduced yet).

LobbyistCovered position, as disclosed
TIMOTHY J REGAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 34 (115th)

Budget/Appropriations BUD

Implementation of H.R. 34 (PL 114-255), 21st Century Cures Act, NIH funding section (no Appropriations Bills introduced yet); Lobbying issues: FY 17/18 NIH Appropriations; FY 17/18 FDA Appropriations; and FY 17/18 EPA Appropriations (no Appropriations Bills introduced yet).

LobbyistCovered position, as disclosed
TIMOTHY J REGAN —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 34 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.